LYMPHOID NEOPLASIA DNA methylation pro fi ling identi fi es two splenic marginal zone lymphoma subgroups with different clinical and genetic features

usage, mutations of NOTCH2 gene, 7q31-32 loss, and histologic transformation. In the High-M set, a number of tumor-suppressor genes were methylated and repressed. PRC2 subunit genes and severalprosurvivallymphomageneswereunmethylatedandoverexpressed.Amodelbasedonthemethylationof3genes( CACNB2, KLF4) caused partial reversion of High-M

[1]  L. Cascione,et al.  The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.

[2]  L. Cascione,et al.  Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response , 2014, Oncotarget.

[3]  Milena Krajnovic,et al.  Hypermethylation of p15 Gene in Diffuse – Large B‐Cell Lymphoma: Association with Less Aggressiveness of the Disease , 2014, Clinical and translational science.

[4]  L. Larocca,et al.  Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker. , 2014, The Journal of molecular diagnostics : JMD.

[5]  A. Salar,et al.  Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation , 2014, Leukemia.

[6]  Yoonjin Cho,et al.  Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. , 2014, Blood.

[7]  Dereje D. Jima,et al.  The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. , 2014, Blood.

[8]  R. Gascoyne,et al.  Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. , 2014, Blood.

[9]  H. Mayani,et al.  Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma , 2014, Leukemia & lymphoma.

[10]  D. Oscier,et al.  Whole Exome Sequencing Identifies Novel Recurrently Mutated Genes in Patients with Splenic Marginal Zone Lymphoma , 2013, PloS one.

[11]  Kidane M. Tekle,et al.  Transcriptional landscapes of emerging autoimmunity: transient aberrations in the targeted tissue’s extracellular milieu precede immune responses in Sjögren’s syndrome , 2013, Arthritis Research & Therapy.

[12]  B. Sander,et al.  A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma , 2013, Epigenetics.

[13]  F. Berger,et al.  Promoter methylation patterns in Richter syndrome affect stem‐cell maintenance and cell cycle regulation and differ from de novo diffuse large B‐cell lymphoma , 2013, British journal of haematology.

[14]  A. Nakagawara,et al.  RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response , 2013, International journal of genomics.

[15]  S. Orkin,et al.  Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer , 2013, Nature chemical biology.

[16]  Yanwen Jiang,et al.  Mechanisms of epigenetic deregulation in lymphoid neoplasms. , 2013, Blood.

[17]  Jos H Beijnen,et al.  Concise drug review: azacitidine and decitabine. , 2013, The oncologist.

[18]  M. Piris,et al.  Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling , 2013, Modern Pathology.

[19]  A. Emili,et al.  Discovery of a chemical probe for the L3MBTL3 methyl-lysine reader domain , 2012, Nature chemical biology.

[20]  S. Pileri,et al.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development , 2012, The Journal of experimental medicine.

[21]  V. Seshan,et al.  HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. , 2011, Blood.

[22]  S. Pileri,et al.  Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. , 2011, Blood.

[23]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[24]  M. Piris,et al.  Immunogenetics features and genomic lesions in splenic marginal zone lymphoma , 2010, British journal of haematology.

[25]  P. Möller,et al.  KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. , 2010, Blood.

[26]  A. Salar,et al.  Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. , 2010, Blood.

[27]  Jie Zhao,et al.  KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway , 2010, Cell Stress and Chaperones.

[28]  K. Gunderson,et al.  Genome-wide DNA methylation profiling using Infinium® assay. , 2009, Epigenomics.

[29]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[30]  K. Kolibaba,et al.  Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. , 2008, Blood.

[31]  A. Salar,et al.  Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria , 2008, Leukemia.

[32]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[33]  J. McPherson,et al.  MethylScreen: DNA methylation density monitoring using quantitative PCR. , 2007, BioTechniques.

[34]  E. Iannitto,et al.  Splenic marginal zone lymphoma: a prognostic model for clinical use. , 2006, Blood.

[35]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Ron Shamir,et al.  EXPANDER – an integrative program suite for microarray data analysis , 2005, BMC Bioinformatics.

[37]  F. Cavalli,et al.  In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  A. Rosenwald,et al.  Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. , 2005, Human pathology.

[39]  J. Delabie,et al.  Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. , 2004, The Journal of molecular diagnostics : JMD.

[40]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[41]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[42]  M. Roussel,et al.  Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.

[43]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[44]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.